Neurosense Therapeutics Ltd (NRSN) — Strategic Asset Allocation Index
Neurosense Therapeutics Ltd (NRSN) has a Strategic Asset Allocation Index of 3.9% as of September 2022. Strategic assets (PP&E of $304.00K plus long-term investments of $-) total $304.00K, measured against net assets of $7.85 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See how leveraged is Neurosense Therapeutics Ltd's balance sheet to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Neurosense Therapeutics Ltd Strategic Asset Allocation Index (2019–2021)
This chart shows how Neurosense Therapeutics Ltd's Strategic Asset Allocation Index has evolved across 3 annual periods from 2019 to 2021. As of September 2022, the index stands at 3.9%, representing strategic assets of $304.00K against net assets of $7.85 Million USD. For live market cap and overall valuation, see Neurosense Therapeutics Ltd market cap and net worth.
Annual Strategic Asset Allocation Index for Neurosense Therapeutics Ltd (2019–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Neurosense Therapeutics Ltd from 2019 to 2021, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Neurosense Therapeutics Ltd (NRSN) shareholders funds for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 0.2% | $19.00K | $19.00K | $- | $9.01 Million | ▼ -1.8 pp |
| 2020 | 2.0% | $13.00K | $13.00K | $- | $659.00K | ▲ +1.2 pp |
| 2019 | 0.8% | $7.00K | $7.00K | $- | $918.00K | — |